The University of Southampton
University of Southampton Institutional Repository

A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo

A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo
A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo

AIMS: The glucagon-like peptide-1 receptor agonists (GLP-1 RAs) exenatide once weekly (ExQW) and liraglutide once daily (QD) are indicated to improve glycaemic control in patients with type 2 diabetes. Although glycaemic control with ExQW versus liraglutide QD 1.8 mg has been directly compared, no studies have compared ExQW with liraglutide QD 1.2 mg or determined the probable relative efficacies of various injectable therapies for glycaemic control; therefore, a network meta-analysis was performed to address these questions.

METHODS: A systematic review identified randomized controlled trials of ≥24 weeks that compared ExQW, liraglutide QD (1.2 mg, 1.8 mg), insulin glargine, exenatide twice daily (ExBID), or placebo. Twenty-two studies evaluating 11 049 patients were included in the network meta-analysis. Mean differences in HbA1c relative to placebo or each other and probability rankings were estimated.

RESULTS: Estimated mean differences in HbA1c versus placebo were -1.15% (95% CrI: -1.31 to -1.00) for ExQW, -1.01% (95% CrI: -1.18 to -0.85) for liraglutide 1.2 mg, and -1.18% (95% CrI: -1.32 to -1.04) for liraglutide 1.8 mg. HbA1c differences for ExQW versus liraglutide 1.2 mg and 1.8 mg were -0.14% (95% CrI: -0.34 to 0.06) and 0.03% (95% CrI: -0.14 to 0.18), respectively. The estimated mean difference in HbA1c between liraglutide 1.2 mg and 1.8 mg was 0.17% (95% CrI: 0.02-0.30). Results were consistent when adjusted for background antihyperglycaemic medications and diabetes duration.

CONCLUSIONS: This network meta-analysis did not identify meaningful differences in HbA1c lowering between ExQW and both liraglutide doses, suggesting that these GLP-1 RAs have similar glycaemic effects.

Blood Glucose/drug effects, Diabetes Mellitus, Type 2/blood, Drug Administration Schedule, Exenatide, Female, Glucagon-Like Peptide 1/administration & dosage, Glycated Hemoglobin A/drug effects, Humans, Hypoglycemic Agents/administration & dosage, Insulin Glargine, Insulin, Long-Acting/administration & dosage, Liraglutide, Male, Peptides/administration & dosage, Treatment Outcome, Venoms/administration & dosage
1462-8902
213-23
Scott, D.A.
19b5fd34-9974-4ae4-8be0-27a693639e20
Boye, K.S.
f8681527-092a-48be-a83f-fb55a7a3218d
Timlin, L.
1caf4840-6468-458f-bbd7-f0796cbb4213
Clark, J.F.
f765c701-13f8-415f-acb3-6faf2dc2004c
Best, J.H.
82319e65-081f-4f40-a79e-b356497222aa
Scott, D.A.
19b5fd34-9974-4ae4-8be0-27a693639e20
Boye, K.S.
f8681527-092a-48be-a83f-fb55a7a3218d
Timlin, L.
1caf4840-6468-458f-bbd7-f0796cbb4213
Clark, J.F.
f765c701-13f8-415f-acb3-6faf2dc2004c
Best, J.H.
82319e65-081f-4f40-a79e-b356497222aa

Scott, D.A., Boye, K.S., Timlin, L., Clark, J.F. and Best, J.H. (2013) A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo. Diabetes, Obesity and Metabolism, 15 (3), 213-23. (doi:10.1111/dom.12007).

Record type: Review

Abstract

AIMS: The glucagon-like peptide-1 receptor agonists (GLP-1 RAs) exenatide once weekly (ExQW) and liraglutide once daily (QD) are indicated to improve glycaemic control in patients with type 2 diabetes. Although glycaemic control with ExQW versus liraglutide QD 1.8 mg has been directly compared, no studies have compared ExQW with liraglutide QD 1.2 mg or determined the probable relative efficacies of various injectable therapies for glycaemic control; therefore, a network meta-analysis was performed to address these questions.

METHODS: A systematic review identified randomized controlled trials of ≥24 weeks that compared ExQW, liraglutide QD (1.2 mg, 1.8 mg), insulin glargine, exenatide twice daily (ExBID), or placebo. Twenty-two studies evaluating 11 049 patients were included in the network meta-analysis. Mean differences in HbA1c relative to placebo or each other and probability rankings were estimated.

RESULTS: Estimated mean differences in HbA1c versus placebo were -1.15% (95% CrI: -1.31 to -1.00) for ExQW, -1.01% (95% CrI: -1.18 to -0.85) for liraglutide 1.2 mg, and -1.18% (95% CrI: -1.32 to -1.04) for liraglutide 1.8 mg. HbA1c differences for ExQW versus liraglutide 1.2 mg and 1.8 mg were -0.14% (95% CrI: -0.34 to 0.06) and 0.03% (95% CrI: -0.14 to 0.18), respectively. The estimated mean difference in HbA1c between liraglutide 1.2 mg and 1.8 mg was 0.17% (95% CrI: 0.02-0.30). Results were consistent when adjusted for background antihyperglycaemic medications and diabetes duration.

CONCLUSIONS: This network meta-analysis did not identify meaningful differences in HbA1c lowering between ExQW and both liraglutide doses, suggesting that these GLP-1 RAs have similar glycaemic effects.

This record has no associated files available for download.

More information

Published date: March 2013
Keywords: Blood Glucose/drug effects, Diabetes Mellitus, Type 2/blood, Drug Administration Schedule, Exenatide, Female, Glucagon-Like Peptide 1/administration & dosage, Glycated Hemoglobin A/drug effects, Humans, Hypoglycemic Agents/administration & dosage, Insulin Glargine, Insulin, Long-Acting/administration & dosage, Liraglutide, Male, Peptides/administration & dosage, Treatment Outcome, Venoms/administration & dosage

Identifiers

Local EPrints ID: 442203
URI: http://eprints.soton.ac.uk/id/eprint/442203
ISSN: 1462-8902
PURE UUID: fe28ec85-969c-4644-8e97-b3a5e7fd1e0b
ORCID for D.A. Scott: ORCID iD orcid.org/0000-0001-6475-8046

Catalogue record

Date deposited: 08 Jul 2020 16:39
Last modified: 17 Mar 2024 04:02

Export record

Altmetrics

Contributors

Author: D.A. Scott ORCID iD
Author: K.S. Boye
Author: L. Timlin
Author: J.F. Clark
Author: J.H. Best

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×